Cargando…
Should All Men with Type 2 Diabetes Be Routinely Prescribed a Phosphodiesterase Type 5 Inhibitor?
Important health problems in men such as type 2 diabetes (T2DM), insulin resistance, erectile dysfunction, benign prostatic hyperplasia and depression have been shown to have to share common pathological processes, such as endothelial dysfunction and inflammation. This paper discusses the role of ph...
Autor principal: | Hackett, Geoffrey |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society for Sexual Medicine and Andrology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308237/ https://www.ncbi.nlm.nih.gov/pubmed/32378365 http://dx.doi.org/10.5534/wjmh.200027 |
Ejemplares similares
-
Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality
por: Anderson, Simon G, et al.
Publicado: (2016) -
Should SGLT2 inhibitors be prescribed in all diabetic type 2 patients?
por: Bernardi, Marco, et al.
Publicado: (2023) -
Statin, testosterone and phosphodiesterase 5-inhibitor treatments and age related mortality in diabetes
por: Hackett, Geoffrey, et al.
Publicado: (2017) -
COVID-19 and Phosphodiesterase Enzyme Type 5 Inhibitors
por: Al-Kuraishy, Hayder M., et al.
Publicado: (2020) -
The Prescribing and Dispensing of Phosphodiesterase Type 5 Inhibitors in South Korea: A Questionnaire Survey of Patient Discomfort
por: Kim, Sang Woo, et al.
Publicado: (2014)